Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer

17 Sept 2022

Abstract excerpt

INTRODUCTION: Prognostic gene expression signatures can be used in combination with classical clinicopathological factors to guide adjuvant chemotherapy decisions in ER-positive, HER2-negative breast cancer. However, long-term outcome data after introduction of genomic testing in the treatment decision-making process are limited. METHODS: In the prospective RASTER study, the tumours of 427 patients with cTanyN0M0...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Cancer Treatment Studies
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36126477
DOI: 10.1016/j.ejca.2022.07.036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerPMID 36126477Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studySemantic proximity Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read ↗

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity Read ↗

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity Read ↗

Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity Read ↗

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerSemantic proximity Read ↗

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read ↗

A breast cancer gene signature for indolent disease.Semantic proximity Read ↗

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER statusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.